General multicomponent strategy for the synthesis of 2-Amino-l,4- diazaheterocycles: Scope, limitations, and utility

European Journal of Organic Chemistry

Volumn , Issue 8, 2010, Pages 1525-1543

  Kysil, Volodymyr ^a   Khvat, Alexander ^a   Tsirulnikov, Sergey ^b   Tkachenko, Sergey ^a   Williams, Caroline ^a,c   Churakova, Marina ^b   Ivachtchenko, Alexandre ^a  

^a CHEMDIV INC   (United States)

^b Chemical Diversity Research Institute   (Russian Federation)

^c ROCHE BIOSCIENCE   (United States)

Author keywords

Cyclization; Lewis acids; Molecular diversity heterocycles; Multicomponent reactions

Indexed keywords

EID: 77649211323     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200901360     Document Type: Article

References (89)

1. a) C. A. Lipinski, F. Lombardo, B. Dominy, P. J. Feeney, Adv. Drug Deliv. Rev. 1997, 23, 3-25;
2. b) G. M. Rishton, Curr. Opin. Chem. Biol 2008, 12, 340-351, and references cited therein.
3. For recent reviews covering IMCRs and their applications see: a) A. Dömling, Chem. Rev. 2006, 106, 17-89;
4. b) I. Akritopou-lou-Zanze, S. W. Djuric, Heterocycles 2007, 73, 125-147;
5. c) I. Akritopoulou-Zanze, Curr. Opin. Chem. Biol. 2008, 12, 324331;
6. d) C. Hulme, in: Multicomponent Reactions (Eds.: J. Zhu, H. Bienaymé), Wiley-VCH, Weinheim, 2005, pp. 311-341;
7. e) C. Hulme, V. Gore, Curr. Med. Chem. 2003, 10, 51-80;
8. f) A. Doemling, in: Multicomponent Reactions (Eds.: J. Zhu, H. Bienaymé), Wiley-VCH, Weinheim, 2005; pp. 76-94;
9. g) S. Marcaccini, T. Torroba, in: Multicomponent Reactions (Eds.: J. Zhu, H. Bienaymé), Wiley-VCH, Weinheim, 2005; pp. 33-75;
10. h) J. Zhu, Eur. J. Org. Chem. 2003, 1133-1144;
11. i) V. Nair, C. Rajesh, A. U. Vinod, S. Bindu, A. R. Sreekanth, J. S. Mathen, L. Ballagopal, Acc. Chem. Res. 2003, 36, 899-907;
12. j) A. Dömling, I. Ugi, Angew. Chem. Int. Ed. 2000, 39, 3168-3210;
13. k) M. A. Mironov, QSAR Comb. Sci. 2006, 25, 423-431;
14. B. Ganem, Acc. Chem. Res. 2009, 42, 463-472;
15. m) C. Hulme, J. Dietrich, Mol. Divers. 2009, 13, 195-207.
16. I. Ugi, R. Meyr, U. Fetzer, C. Steinbrückner, Angew. Chem. 1959, 71, 386.
17. For the excellent most recent comprehensive review of less conventional versus "classic" Ugi IMCR interactions between isocyanides and iminium species following by trapping (including intramolecular) of nitrilium cation by N-, C-, O-, and S-nucleophiles see: L. El Kaim, L. Grimaud, Tetrahedron 2009, 65, 2153-2171.
18. C. Blackburn, B. Guan, K. Shiosaki, S. Tsai, Tetrahedron Lett. 1998, 39, 3635-3638.
19. K. Groebke, L. Weber, F. Mehlin, Synlett 1998, 661-663.
20. H. Bienaymé, K. Bouzid, Angew. Chem. Int. Ed. 1998, 37, 2234-2237.
21. For the most recent applications see:a) T. Kercher, Ch. Rao, J. R. Bencsik, J. A. Josey, J. Comb. Chem. 2007, 9, 1177-1187;
22. b) T. Meng, Z. Zhang, D. Hu, L. Lin, J. Ding, X. Wang, J. Shen, J. Comb. Chem. 2007, 9, 739-741.
23. S. Carballares, J. F. Espinosa, Org. Lett. 2005, 7, 2329-2331.
24. K. Illgen, S. Nerdinger, D. Behnke, C. Friedrich, Org. Lett. 2005, 7, 2517-2518.
25. K. Illgen, S. Nerdinger, D. Behnke, C. Friedrich, Org. Lett. 2005, 7, 39-42.
26. V. Franckevičius, D. A. Longbottom, R. M. Turner, S. V. Ley, Synthesis 2006, 19, 3215-3223.
27. W. Keung, F. Bakir, A. P. Patron, D. Rogers, Ch. D. Priest, V. Darmohusodo, Tetrahedron Lett. 2004, 45, 733-737.
28. In contrast with Sc(OTf)3-catalyzed reactions, bis-secondary diamines mimic primary amines with the formation of linear products in the presence of acetic acid, (i.e., under "classic" Ugi conditions). For reports of this Ugi reaction extension see:
29. a) G. B. Giovenzana, G. C. Iron, S. Di Paola, I. G. Menegotto, T. Pirali, Angew. Chem. Int. Ed. 2006, 45, 1099-1102;
30. b) T. Pirali, G. Callipari, E. Ercolano, A. A. Genazzani, G. B. Giovenzana, G. C. Tron, Org. Lett. 2008, 10, 4199-4202.
31. a) V. Kysil, S. Tkachenko, A. Khvat, C. Williams, S. Tsirulnikov, M. Churakova, A. Ivachtchenko, Tetrahedron Lett. 2007, 48, 6239-6244;
32. b) V. Kysil, A. Khvat, S. Tsirulnikov, S. Tkachenko, A. Ivachtchenko, Tetrahedron Lett. 2009, 50, 2854-2856.
33. For patent information, see also: A. V. Ivashchenko, A. P. Ilyin, V. M. Kysil, A. S. Trifilenkov, S. A. Tsirulnikov, A. M. Shkirando, M. V. Churakova, I. O. Lomakina, V. V. Potapov, A. I. Zamaletdinova, S. Y. Tkachenko, D. V. Kravchenko, A. V. Khvat, I. M. Okun, A. S. Kyselev, PCT Int. Appl. 2007, WO2007117180.
34. A. Shaabani, A. Maleki, J. Moghimi-Rad, J. Org. Chem. 2007, 72, 6309-6311.
35. M. Krasavin, V. Parchinsky, Synlett 2008, 5, 645-648.
36. A. Shaabani, A. Maleki, H. Mofakham, H. R. Khavasi, J. Comb. Chem. 2008, 10, 323-326.
37. For examples of naturally occurring 2-amin.opyrazmes see: a) Z. Chen, J. Fan, A. S. Kende J. Org. Chem. 2004, 69, 79-85;
38. b) S. Martin-Santamaria, R. Corzo-Suarez, C. Avendano, M. Espada, F. Gago, S. Garcia-Granda, H. S. Rzepa, J. Org. Chem. 2002, 67, 2013-2018.
39. For the most recent representative examples of biologically active compounds containing the 2-aminopyrazine core see: a) X. Du, D. J. Gustin, X. Chena, J. Duquette, L. R. McGee, Z. Wang, K. Ebsworth, K. Henne, B. Lemon, J. Ma, S. Miao, E. Sabalan, T. J. Sullivan, G. Tonn, T. L. Collins, J. C. Medina, Bioorg. Med. Chem. Lett. 2009, 19, 5200.5204;
40. b) D. Kim, L. Wang, M. Beconi, G. J. Eiermann, M. H. Fisher, H. He, G. J. Hickey, J. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M. E. McCan, R. A. Patel, A. Petrov, G. Scapin, S. B. Patel, R. S. Roy, J. K. Wu, M. J. Wyvratt, B. B. Zhang, L. Zhu, N. A. Thornberry, A. E. Weber, J. Med. Chem. 2005, 48, 141-151;
41. c)V. L. Damaraju, K. F. Hamilton, M. L. Seth-Smith, C. E. Cass, M. B. Sawyer, Mol. Pharmacol. 2005, 67, 453-459;
42. d) D. J.Wustrow, G. D. Maynard, J. Yuan, H. Zhao, J. Mao, Q. Guo, M. Kershaw, J. Hammer, R. Brodbeck, K. E. Near, D. Zhou, D. S. Beers, B. L. Chenard, J. E. Krause, A. J. Hutchison, Bioorg. Med. Chem. Lett. 2008, 18, 3376-3381;
43. e) Z. Pei, X. Li,T. W von. Geldern, D. J. Madar, K. Longenecker, H. Yong, T. H. Lubben, K. D. Stewart, B. A. Zinker, B. J. Backes, A. S. Judd, M. Mulheril, S. J. Bailaron, M. A. Stashko, A. K. Mika, D. W A. Beno, G. A. Reinhart, R. M. Fryer, L. C. Preusser, A. J. Kempf-Grote, H. L. Sham, J. M. Trevillyan, J. Med. Chem. 2006, 49, 6439-6442;
44. f) P. Lin, L. Chang, R. J. DeVita, J. R. Young, R. Eid, X. Tong, S. Zheng, R. G. Ball, N. N. Tsou, G. G. Chicchi, M. M. Kurtz, K.-L. C. Tsao, A. Wheeldon, E. J. Carlson, W Eng, H. D. Burns, R. J. Hargreaves, S. G. Mills, Bioorg. Med. Chem. Lett. 2007, 17, 5191-5198;
45. g) D. Kim, J. E. Kowalchick, S. D. Edmondson, A. Mastracchio, J. Xu, G. J. Eiermann, B. Leiting, J. K. Wu, K. D. Pryor, R. A. Patel, II. He, K. A. Lyons, N. A. Thornberry, A. E. Weber, Bioorg. Med. Chem. Lett. 2007, 17, 3373-3377.
46. For example of anticancer multidrug resistance reversal caused, by 2-ammopyrazine-containing agents, see: C. Mendez-Vidal, A. R. Quesada, Cancer Lett. 1998, 132, 45-50.
47. For the most recent representative examples of biological active compounds containing the 2-amino(imino)quinoxaline core see:
48. a) G. Marverti, A. Ligabue, G. Paglietti, P. Corona, S. Piras, G. Vitale, D. Guerrieri, R. Luciani, M. P. Costi, C. Frassineti, M. S. Moruzzi, Eur. J. Pharmacol. 2009, 615, 17-26;
49. b) R. A. Smits, H. D. Lim, A. Hanzer, O. P. Zuiderveld, E. Guaita, M. Adami, G. Coruzzi, R. Leurs, I. J. de Esch, J. Med. Chem. 2008, 51, 2457-2467;
50. c) H. C. Shen, M. J. Szymonifka, D. Kharbanda, Q. Deng, E. Carballo-Jane, K. K. Wu, T. J. Wu, K. Cheng, N. Ren, T. Q. Cai, A. K. Taggart, J. Wang, X. long, M. G. Waters, M. L. Hammond, J. R. Tata, S. L. Colletti, Bioorg. Med. Chem. Lett. 2007, 17, 6723-6728;
51. d) M. Y. Chu- Moyer, W. E. Ballinger, D. A. Beebe, R. Berger, J. B. Coutelier, W. W. Day, J. Li, B. L. Mylari, P. J. Oates, R. M. Weekly, J. Med. Chem. 2002, 45, 511-528;
52. e) J. J. Li, K. G. Carson, B. K. Trivedi, W. S. Yue, Q. Ye, R. A. Glynn, S. R. Miller, D. T. Connor, B. D. Roth, J. R. Luly, J. E. Low, D. J. Heilig, W. Yang, S. Qin, S. Hunt, Bioorg. Med. Chem. 2003, 11, 3777-3790;
53. f) A. Carta, M. Loriga, G. Paglietti, A. Mattana, P. L. Fiori, P. Mollicotti, L. Sechi, S. Zanetti, Eur. J. Med. Chem. Chim. Ther. 2004, 39, 195-204;
54. g) E. R. El-Bendary, F. E. Goda, A. R. Maarouf, F. A. .Badria, Sci. Pharm. 2004, 72, 175-186;
55. h) S. Y. Hassan, S. N. Khattab, A. A. Bekhit, A. Amer, Bioorg. Med. Chem. Lett. 2006, 16, 1753-1756;
56. i) S. Piras, M. Loriga, A. Carta, G. Paglietti, M. P. Costi, S. Ferrari, J. Heterocycl. Chem. 2006, 43, 541-548;
57. j) K. M. Amin, M. M. F. Ismail, E. Noaman, D. H. Soliman, Y. A. Ammar, Bioorg. Med Chem. 2006, 14, 6917-6923.
58. a.) S. Witek, A. Bielawska, J. Bielawski, Heterocycles 1980, 14, 1313-1317;
59. b) C. Chapuis, A. Gauvreau, A. Klaebe, A. Lattes, J. J. Perie, Bull. Soc. Chim. Fr. 1973, 977-985;
60. c) G. Parinell, R.Mulhaupt, J. Org. Chem. 1990, 55, 1772-1779;
61. d) L. Lázár, A.Göblyös, F. Evanics, G. Bernáth F. Fülöp, Tetrahedron 1998, 54, 13639-13644;
62. e) O. Maloshitskaya, J. Sinkkonen, V. V. Ovcharenko, K. N. Zelenin, K. Pihlaj, Tetrahedron 2004, 60, 6913-6921, and references therein.
63. For representative examples of isocyanide double addition/insertion, see: a) M. Tobisu, S. Ito, A. Kitajima, N. Chatani, Org. Lett. 2008, 10, 5223-5225;
64. b) M. Tobisu, A. Kitajima, S. Yoshioka, I. Hyodo, M. Oshita, N. Chatani, J. Am. Chem. Soc. 2007, 129, 11431-11437;
65. c) J. D. Winkler, S. M. Asselin, Org. Lett. 2006, 8, 3975-3977;
66. d) V. Nair, R. S. Menon, A. Deepthi, B. R. Devi, A. T. Biju, Tetrahedron Lett. 2005, 46, 1337-1339;
67. e) M. Oshita, K. Yamashita, M. Tobisu, N. Chatani, J. Am. Chem. Soc. 2005, 127, 761-766;
68. f) S. Yoshioka, M. Oshita, M. Tobisu, N. Chatani, Org. Lett. 2005, 7, 3697-3699;
69. g) N. Chat- ani, M. Oshita, M. Tobisu, Y. Ishii, S. Murai, J. Am. Chem. Soc. 2003, 125, 7812-7813;
70. h) G. Bez, C.-G. Zhao, Org. Lett, 2003, 5, 4991-1993;
71. i) A. P. Kozikowski, P. U. Park, J. Org. Chem. 1984, 49, 1674-1676.
72. For a review, see: A. D. Dilman, S. L. Ioffe, Chem. Rev. 2003, 103, 733-772.
73. S. E. Denmark, Y. Fan, J. Org. Chem. 2005, 70, 9667-9776.
74. a) M. Yamanaka, A. Nishida, M. Nakagawa, Org. Lett. 2000, 2, 159-161;
75. b) R. Tsuji, M. Yamanaka, A. Nishida, M. Nakagawa, Chem. Lett. 2002, 428-429;
76. c) M. Yamanaka, A. Nishida, M. Nakagawa, J. Org. Chem. 2003, 68, 3112-3120.
77. a) R. M. Sanchez-Martin, S. Mittoo, M. Bradley, in: Current Topics in Medicinal Chemistry (Ed.: Z. Rankovic), Bentham Sci. Publ. 2004, vol.4 (7), pp. 653-669;
78. b) A. Thayer, Chem. Eng. News 2005, 83, 55-58;
79. c) Ch. J. Welch, J. Albaneze-Walker, W. R. Leonard, M. Biba, J. DaSilva, D. Henderson, B. Laing, D. J. Mathre, S. Spencer, X. Bu, T Wang, Org. Process Res. Dev. 2005, 9, 198-205.
80. S. E. Denmark, Y. Fan, J. Am. Chem. Soc. 2003, 125, 78257827.
81. S. V. Ryabukhin, A. S. Plaskon, D. M. Volochnyuk, A. A. Tolmachev, Synthesis 2006, 3715-3726.
82. M. M. Heravi, B. Baghemejad, H. A. Oskooie, Tetrahedron Lett. 2009, 50, 767-769.
83. M. Eguchi, M. Kahn, Mini-Rev. Med. Chem. 2002, 2, 447-462.
84. a) Ch. Blackburn, B. Guan, Tetrahedron Lett. 2000, 41, 14951500;
85. b) J. Schwerkoske, T. Masquelin, T. Perun, C. Hulme, 'Tetrahedron Lett. 2005, 46, 8355-8357;
86. c) E. F. DiMauro, J. M. Kennedi, J. Org. Chem. 2007, 72, 1013-1016.
87. In a recent publication from our group, TMSCl has been shown to be an effective promoter of Groebke-Blackburn-Bienamé-type MCRs involving [l,3,4]thiadiazol-2-amines, which had proven to be poorly reactive under traditional conditions. For details see: M. Krasavin, S. Tsirulnikov, M. Nikulnikov, V. Kysil, A. Ivachtchenko, Tetrahedron Lett. 2008, 49, 5241-5243.
88. 13C NMR spectrum.
89. 3 group was not identified because of its low intensity.